-
Management of Von Hippel-Lindau Syndrome
10 Jul 2025 10:39 GMT
… . Tadross is a fourth-year medical student at the University of … Miami Miller School of Medicine. Dr. Williams is an associate … . Solitary retinal capillary hemangioma: Hereditary (von Hippel-Lindau disease) or nonhereditary? Arch Ophthalmol 2001 …
-
Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors
19 Oct 2025 02:16 GMT
… Hormonal Disorders, were published today in the New England Journal of Medicine … the HIF-2α protein. In healthy cells this protein adjusts to … approves belzutifan for adults with von Hippel‑Lindau (VHL) disease who require treatment for …
-
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients
18 Oct 2025 10:58 GMT
… Hormonal Disorders, were published today in the New England Journal of Medicine … the HIF-2α protein. In healthy cells this protein adjusts to … approves belzutifan for adults with von Hippel‑Lindau (VHL) disease who require treatment for …
-
Disease Monitoring and Treatment Patterns of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States.
06 May 2025 14:09 GMT
Patients with von Hippel-Lindau (VHL) disease are predisposed to … . This study evaluated disease monitoring and treatment patterns … drug use, disease monitoring procedures, and medical specialist visits in … .61]), and visited more medical specialists (1.82 [95% …
-
Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease.
28 Apr 2025 07:13 GMT
… understanding the natural history of von Hippel-Lindau (VHL) disease-associated renal cell carcinoma … of surgery, including chronic kidney disease (CKD), and mortality. Radiographic … patients, with high rates of disease progression, surgery, and metastasis …
-
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.
16 Apr 2025 13:30 GMT
… belzutifan as systemic treatment for von Hippel-Lindau disease-associated renal cell carcinoma.
… of the National Institutes of Health, National Cancer Institute Center … Boston, MA, USA., Vanderbilt University Medical Center, Nashville, TN, USA., University …
-
Kelun-Biotech divulges new GTPase KRAS G12D mutant degradation inducers
15 Oct 2025 19:06 GMT
… chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety …
-
China NMPA approves Merck's Welireg to treat adult patients with certain types of von Hippel─Lindau disease─associated tumours
23 Nov 2024 10:12 GMT
… Canada, announced that the National Medical Products Administration (NMPA) in China … and in combination with other medicines.
LITESPARK-004 is an open … and CNS hemangioblastomas.
Von Hippel-Lindau disease is a rare genetic disease that impacts an …
-
ESMO 2025: Belzutifan Demonstrates Tumor Reduction and Symptom Relief in Patients with Rare Neuroendocrine Tumors
18 Oct 2025 09:31 GMT
… adaptation to oxygen fluctuations. In healthy physiology, HIF-2α is … efficacy in cancers such as von Hippel-Lindau disease-associated tumors and advanced renal … Hormonal Disorders
New England Journal of Medicine – Article
European Society for Medical Oncology …
-
Gastrointestinal Neuroendocrine Tumors Market Set to Surge by 2034 Amidst Advancements in Treatment Options | DelveInsight
15 Oct 2025 23:24 GMT
… growth driven by increasing disease prevalence, improved diagnostic … unlocking opportunities for medical innovation and economic … aggressively. The World Health Organization (WHO) has … NETs, including pituitary adenomas, Von Hippel–Lindau (VHL) syndrome, and …
About
© 1995-2025